FDA fast-tracking of a therapy involving Precision BioSciences, Arrowhead Pharmaceuticals, and Gilead Sciences began on July 1, 2025.
1 report, 0 independent
Updated Jul 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA fast-tracking of a therapy involving Precision BioSciences, Arrowhead Pharmaceuticals, and Gilead Sciences began on July 1, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Arrowhead Pharmaceuticals issued a press release from its offices in Pasadena on June 23, 2025.Sub-event
- FDA fast-tracked a therapy on July 1, 2025, involving the listed companies.
Keep exploring
The entities involved
- FDA
-
Precision BioSciences
American gene editing company
Nothing else this week.
-
Arrowhead Pharmaceuticals
biopharmaceutical company
Nothing else this week.
-
Gilead Sciences
American company
Related events
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- The FDA is monitoring drug industry practices and pricing, utilizing studies published by JAMA.
- FDA approval enables commercial availability for a product associated with Indianapolis.
Coverage
Newest first; wire copies grouped- Unknown outlet